Alloy Therapeutics

Executive Summary

Alloy Therapeutics is a privately held biotechnology company that has pioneered a collaborative discovery platform for therapeutic antibodies. Founded in 2017 and headquartered in Boston, the company operates a unique 'platform-as-a-service' model centered on its ATX-Gx technology, which includes a suite of transgenic animals and associated services to generate fully human antibodies for partner organizations. By democratizing access to industry-leading antibody discovery tools, Alloy aims to accelerate the development of novel therapeutics across oncology, immunology, and infectious disease. The company has raised approximately $42 million in funding and employs between 200 and 500 staff, positioning itself as a key enabler in the biopharmaceutical ecosystem. Its platform approach allows partners to bypass the significant capital expenditure typically required for in-house antibody generation, driving efficiency and fostering innovation across the industry. With a growing network of collaborations and a focus on expanding its transgenic animal models, Alloy Therapeutics is poised to capture a substantial share of the outsourced antibody discovery market.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major partnership with a top-20 pharmaceutical company70% success
• Q4 2026Launch of a new transgenic platform for bispecific antibody discovery60% success
• Q2 2027Closure of a Series C financing round exceeding $75 million75% success